Drug intelligence / Profile preview

AX-011

Development stage: Preclinical
Lead developer: Axiom Biosciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

AX-011 is an engineered mesenchymal stem cell (eMSC) therapy being developed by Axiom Biosciences for the treatment of burns. The program is currently in preclinical development and is supported by funding from the U.S. Department of Defense (DoD). Axiom Biosciences is utilizing the FDA Animal Rule pathway for its development, a regulatory track typically reserved for products where human efficacy studies are not ethical or feasible. The therapy leverages engineered MSCs to potentially enhance wound healing, modulate inflammation, and improve tissue regeneration in severe burn injuries.

Beyond the preview

Go deeper on AX-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-011.

Explore the full profile